β-Amyloid (1-42) peptide deposition in the brain is one of the two hallmarks of Alzheimer’s disease (AD), besides neurofibrillary tangles. Pathological changes in the β-Amyloid metabolism are the earliest alterations during AD development. These changes are reflected by the decrease in the CSF concentrations of β-Amyloid (1-42) as well as by the increase in the brain uptake of the specific tracers on the β-Amyloid PET.1
Elecsys β Amyloid (1 42) CSF (Abeta42) is an in vitro diagnostic immunoassay intended for the quantitative determination of the β amyloid (1 42) protein concentration in human cerebrospinal fluid (CSF).
cobas e 601, cobas e 602